Compare Gap Inc (GAP) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Novartis AG — how do they compare? Gap Inc trades at $20.81 (market cap $7.30B), while Novartis AG trades at $151.77 (market cap $287.66B). The key difference: Novartis AG is far larger — about 39.4× Gap Inc's market cap, and Gap Inc pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| GAP | NVS | |
|---|---|---|
Market Cap | $7.30B | $287.66B |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $168.62 |
52-Week Low | $18.35 | $113.50 |
Enterprise Value | $10.38B | $327.68B |
Dividend Yield | 3.45% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $20.13, up 1.67% today, with a bullish technical signal but mixed moving averages. The company shows strong profitability with a 6.25% net income margin and 27.58% ROE, supported by positive earnings beats in recent quarters. Revenue has stabilized around $15B, and cash flow from operations remains robust at $1.49B for 2025. Recent news highlights Gap's digital transformation and Athleta brand turnaround efforts, though legal investigations present headwinds.
The stock appears undervalued with a P/E of 8.05 and consensus price target of $27.00, implying 34% upside. Key opportunities include earnings growth and margin expansion, but risks involve competitive pressures and ongoing legal probes. Analyst sentiment is mixed with 39.58% buy ratings, suggesting cautious optimism for value-oriented investors.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
